Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial
Moritz Fürstenau·B Eichhorst·Sandra Robrecht·Emelie Rotbain·Laura Eurelings·Adam Giza·Julia von Tresckow·Can Zhang·Michael Gregor·Patrick Thornton·Philipp B. Staber·Tamar Tadmor·Vesa Lindström·Gunnar Juliusson·Ann Janssens·Caspar da Cunha-Bang·Christof Schneider·Yair Herishanu·Derville O'Shea·Michaël Baumann·Anouk Andrea Widmer·Thomas Nösslinger·C Grandjean Poulsen·Henrik Frederiksen·Kourosh Lotfi·Juha Ranti·Lisbeth Enggaard·Gerjo A. Velders·Marie-Christiane Madeleine Vekemans·Koen de Heer·T. J. F. Snijders·Claire Siemes·C.‐M. Wendtner·Wolfgang Knauf·Alexander Kroeber·Mark‐Oliver Zahn·Thomas Illmer·Björn Schöttker·Florian Simon·Anna-Maria Fink·Kirsten Fischer·Ronald D'Brot·Emily Eva Holmes·Karl-Anton Kreuzer·Matthias Ritgen·Eugen Tausch·Stephan Stilgenbauer·Mark-David Levin·Michael J Hallek·Arnon P. Kater·Monika Brüggemann·Carsten Utoft Niemann
Fixed-duration venetoclax combinations have become a standard first-line treatment in chronic lymphocytic leukemia (CLL). The phase 3 CLL13/GAIA trial assesses three time-limited combinations: venetoclax-rituximab (RV), venetoclax-obinutuzumab (GV), and venetoclax-obinutuzumab-ibrutinib (GIV) compared to chemoimmunotherapy (CIT). Fit patients with CLL without TP53 aberrations were randomized between six cycles of CIT (fludarabine-cyclophosphamide-rituximab [FCR], bendamustine-rituximab [BR]) or